Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studiesOct 16Weekly roundup, 7 itemsianalumabNovartis
Novartis withdraws planned phase 2 retreatment study of ianalumab in ITP and wAIHAOct 15Trial updateianalumabNovartis
Sign inSign in